NCT00064467
Completed
Phase 3
An 8 Week, Multicenter, Randomized, Double-blind, Placebo Controlled Comparison of the Efficacy of Extended Release Bupropion Hydrochloride and Placebo in the Treatment of Adult Outpatients With Major Depressive Disorder With Lethargic Symptoms
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Epilepsy
- Sponsor
- GlaxoSmithKline
- Enrollment
- 268
- Locations
- 1
- Primary Endpoint
- Change from randomization on the Inventory of Depressive Symptomatology, self report and clinician rated.
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.
Detailed Description
A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for eight weeks for the treatment of adult outpatients with major depressive disorder including symptoms of decreased energy, pleasure, and interest
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Change from randomization on the Inventory of Depressive Symptomatology, self report and clinician rated.
Secondary Outcomes
- Percent of responders. Percent of remitters. Quality of Life Enjoyment and Satisfaction Questionnaire.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive DisorderMajor Depressive DisorderNCT01052077Otsuka Pharmaceutical Development & Commercialization, Inc.773
Completed
Phase 2
A Study to Test Different Doses of BI 1569912 in People With DepressionDepressive Disorder, MajorNCT06558344Boehringer Ingelheim224
Terminated
Phase 1
A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive DisorderMajor Depressive Disorder (MDD)NCT06618118AbbVie20
Completed
Phase 2
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive MedicineDepressive Disorder, MajorNCT06280235Boehringer Ingelheim84
Recruiting
Not Applicable
Relevance of a Telemedicine Monitoring in the Management of DepressionMajor Depressive DisorderNCT06076317Assistance Publique - Hôpitaux de Paris836